These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8886556)

  • 1. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment.
    Inoue I; Takahashi K; Kikuchi C; Katayama S
    Diabetes Care; 1996 Oct; 19(10):1103-7. PubMed ID: 8886556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis.
    Donner MG; Parhofer KG; Richter WO; Schwandt P
    Metabolism; 1999 Jul; 48(7):881-6. PubMed ID: 10421230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease.
    Tsumura M; Kinouchi T; Ono S; Nakajima T; Komoda T
    Clin Chim Acta; 2001 Dec; 314(1-2):27-37. PubMed ID: 11718676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia.
    Napoli C; Ambrosio G; Scarpato N; Corso G; Palumbo G; D'Armiento FP; Mancini FP; Malorni A; Formisano S; Ruocco A; Calí A; Chiariello M
    Am Heart J; 1997 May; 133(5):585-95. PubMed ID: 9141382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Ushiyama C; Osada S; Inoue T; Shimada N; Koide H
    J Diabetes Complications; 2003; 17(6):349-54. PubMed ID: 14583180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
    Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
    ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
    Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
    Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.
    Julier K; Mackness MI; Dean JD; Durrington PN
    Diabet Med; 1999 May; 16(5):415-23. PubMed ID: 10342342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
    Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
    Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability.
    Kroon AA; Demacker PN; Kleinveld HA; Stalenhoef AF
    Atherosclerosis; 1999 Nov; 147(1):105-13. PubMed ID: 10525131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition?
    Moro E; Alessandrini P; Zambon C; Pianetti S; Pais M; Cazzolato G; Bon GB
    Diabet Med; 1999 Aug; 16(8):663-9. PubMed ID: 10477211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
    Dieplinger H; Schoenfeld PY; Fielding CJ
    J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis.
    Bräutigam C; Engelmann B; Reiss D; Reinhardt U; Thiery J; Richter WO; Brosche T
    Atherosclerosis; 1996 Jan; 119(1):77-88. PubMed ID: 8929259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma lipid composition and LDL oxidation.
    Brizzi P; Tonolo G; Carusillo F; Malaguarnera M; Maioli M; Musumeci S
    Clin Chem Lab Med; 2003 Jan; 41(1):56-60. PubMed ID: 12636050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation.
    Moro E; Zambon C; Pianetti S; Cazzolato G; Pais M; Bittolo Bon G
    Acta Diabetol; 1998 Oct; 35(3):161-4. PubMed ID: 9840454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia.
    Linseisen J; Wilhelm M; Hoffmann J; Hailer S; Keller C; Wolfram G
    Eur J Med Res; 1999 Oct; 4(10):433-41. PubMed ID: 10527957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin inhibits oxidative modification of low-density lipoprotein particles in normolipidemic post-menopausal women.
    Wakatsuki A; Okatani Y; Ikenoue N; Izumiya C; Kaneda C
    J Pineal Res; 2000 Apr; 28(3):136-42. PubMed ID: 10739299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients.
    Beaudeux JL; Guillausseau PJ; Peynet J; Flourie F; Assayag M; Tielmans D; Warnet A; Rousselet F
    Clin Chim Acta; 1995 Aug; 239(2):131-41. PubMed ID: 8542651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration.
    Panzetta O; Cominacini L; Garbin U; Fratta Pasini A; Gammaro L; Bianco F; Davoli A; Campagnola M; De Santis A; Pastorino AM
    Clin Nephrol; 1995 Nov; 44(5):303-9. PubMed ID: 8605710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Composition of LDL as determinant of its susceptibility to in vitro oxidation in patients with well-controlled type 2 diabetes.
    Scheffer PG; Bakker SJ; Popp-Snijders C; Heine RJ; Schutgens RB; Teerlink T
    Diabetes Metab Res Rev; 2001; 17(6):459-66. PubMed ID: 11757082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.